Rifampin
FULL PRESCRIBING INFORMATION: CONTENTS*
- RIFAMPIN DESCRIPTION
- CLINICAL PHARMACOLOGY
- INDICATIONS & USAGE
- RIFAMPIN CONTRAINDICATIONS
- WARNINGS
- PRECAUTIONS
- INFORMATION FOR PATIENTS
- LABORATORY TESTS
- DRUG INTERACTIONS
- DRUG & OR LABORATORY TEST INTERACTIONS
- CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY
- PREGNANCY
- NURSING MOTHERS
- PEDIATRIC USE
- GERIATRIC USE
- RIFAMPIN ADVERSE REACTIONS
- OVERDOSAGE
- DOSAGE & ADMINISTRATION
- HOW SUPPLIED
- REFERENCES
- INACTIVE INGREDIENT
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION
FULL PRESCRIBING INFORMATION
RIFAMPIN DESCRIPTION
DESCRIPTION
CLINICAL PHARMACOLOGY
Oral AdministrationWARNINGS
Pediatrics
Oral Administration
Microbiology
INDICATIONS AND USAGE
INDICATIONS AND USAGE
Susceptibility Tests
CLINICAL PHARMACOLOGY
INDICATIONS AND USAGE
Microorganism MIC (mcg/mL)
Staphylococcus aureus ATCC 29213 0.008 - 0.06
Enterococcus faecalis ATCC 29212 1 - 4
Escherichia coli ATCC 25922 8 - 32
Pseudomonas aeruginosa ATCC 27853 32 - 64
Haemophilus influenzae ATCC 49247 0.25 - 1
Diffusion Techniques: Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure3,4 that has been recommended for use with disks to test the susceptibility of microorganisms to rifampin uses the 5 mcg rifampin disk. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for rifampin.
Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg rifampin disk should be interpreted according to the following criteria for Neisseria meningitidis.
Zone Diameter (mm)Interpretation20(S) Susceptible17-19(I) Intermediate16(R) ResistantInterpretation should be as stated above for results using dilution techniques.
As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms. The use of these microorganisms does not imply clinical efficacy (seeINDICATIONS AND USAGE
MicroorganismZone Diameter (mm)S. aureusATCC 2592326 - 34E. coliATCC 259228 - 10H. influenzaeATCC 4924722 - 30
INDICATIONS & USAGE
Tuberculosis
Meningococcal Carriers
WARNINGS
RIFAMPIN CONTRAINDICATIONS
CONTRAINDICATIONSWARNINGS
WARNINGS
WARNINGSPRECAUTIONS
GeneralINFORMATION FOR PATIENTS
LABORATORY TESTS
DRUG INTERACTIONS
Enzyme InductionDRUG & OR LABORATORY TEST INTERACTIONS
Drug/Laboratory InteractionsCARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY
Carcinogenesis, Mutagenesis, Impairment of FertilityPREGNANCY
Pregnancy-Teratogenic EffectsPregnancy-Non-Teratogenic Effects
NURSING MOTHERS
Nursing MothersPEDIATRIC USE
Pediatric UseCLINICAL PHARMACOLOGYPediatricsDOSAGE AND ADMINISTRATION.
GERIATRIC USE
Geriatric UseWARNINGS
RIFAMPIN ADVERSE REACTIONS
GastrointestinalHematologic
Central Nervous System
Ocular
Endocrine
Renal
Dermatologic
Hypersensitivity Reactions
Miscellaneous
OVERDOSAGE
Signs and SymptomsAcute Toxicity
Treatment
DOSAGE & ADMINISTRATION
INDICATIONS AND USAGECLINICAL PHARMACOLOGYTuberculosis
Incompatibilities:
Meningococcal Carriers
Preparation of Extemporaneous Oral Suspension
HOW SUPPLIED
Storage:
REFERENCES
INACTIVE INGREDIENT
INACTIVE INGREDIENTS:SILICON DIOXIDE
STARCH, CORN
DOCUSATE SODIUM
FD&C BLUE NO. 1
FD&C BLUE NO. 2
FD&C RED NO. 40
GELATIN
MAGNESIUM STEARATE
CELLULOSE, MICROCRYSTALLINE
SODIUM BENZOATE
SODIUM LAURYL SULFATE
FERROSOFERRIC OXIDE
TALC
TITANIUM DIOXIDE
D&C YELLOW NO. 10
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION
RifampinRifampin CAPSULE
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
